CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation

被引：14

作者：

Pan, Minggui

Santamaria, Monica

Wollman, David B.

机构：

[1] Kaiser Permanente Med Ctr, Div Hematol & Oncol, Santa Clara, CA 95051 USA

[2] Kaiser Permanente Med Ctr, Dept Pathol, Santa Clara, CA 95051 USA

[3] Kaiser Permanente Med Ctr, Dept Radiol, Santa Clara, CA 95051 USA

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 10期

关键词：

CNS metastasis; EGFR; erlotinib; gefitinib; non-small-cell lung cancer;

D O I：

10.1038/ncponc0931

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background A 73-year-old Asian man with a history of lipidemia, hypertension and myocardial infarction presented with dizziness, decreased appetite, weight loss, nonproductive cough and fatigue. His physical performance status was good, and physical examination was unremarkable except for lower-extremity pitting edema. Investigations Physical examination, brain MRI, CT scans of the chest, abdomen and pelvis, bone scan, CT scan-guided biopsy, hematoxylin and eosin staining, EGFR mutational analysis, and chest X-ray. Diagnosis Stage IV non-small-cell lung cancer with brain metastasis. Management Oral erlotinib 150 mg daily for 10 months and ongoing, and whole-brain irradiation.

引用

收藏

页码：603 / 607

页数：5

相关论文

共 19 条

[1] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[2] Gefitinib in patients with brain metastases from non-small-cell lung cancer:: a prospective trial [J].

Ceresoli, GL ;

Cappuzzo, F ;

Gregorc, V ;

Bartolini, S ;

Crinó, L ;

Villa, E .

ANNALS OF ONCOLOGY, 2004, 15 (07) :1042-1047

[3] Gefitinib response of erlotinib-refractory lung cancer involving meninges -: role of EGFR mutation [J].

Choong, NW ;

Dietrich, S ;

Seiwert, TY ;

Tretiakova, MS ;

Nallasura, V ;

Davies, GC ;

Lipkowitz, S ;

Husain, AN ;

Salgia, R ;

Ma, PC .

NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01) :50-57

[4] Non-small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation [J].

Das, Amit K. ;

Sato, Mitsuo ;

Story, Michael D. ;

Peyton, Michael ;

Graves, Robert ;

Redpath, Stella ;

Girard, Luc ;

Gazdar, Adi F. ;

Shay, Jerry W. ;

Minna, John D. ;

Nirodi, Chaitanya S. .

CANCER RESEARCH, 2006, 66 (19) :9601-9608

[5] Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study [J].

Giaccone, Giuseppe ;

Ruiz, Marielle Gallegos ;

Le Chevalier, Thierry ;

Thatcher, Nick ;

Smit, Egbert ;

Rodriguez, Jose Antonio ;

Janne, Pasi ;

Oulid-Aissa, Dalila ;

Soria, Jean-Charles .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6049-6055

[6] Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer [J].

Hotta, K ;

Kiura, K ;

Ueoka, H ;

Tabata, M ;

Fujiwara, K ;

Kozuki, T ;

Okada, T ;

Hisamoto, A ;

Tanimoto, M .

LUNG CANCER, 2004, 46 (02) :255-261

[7] Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib [J].

Jackman, David M. ;

Holmes, Alison J. ;

Lindeman, Neal ;

Wen, Patrick Y. ;

Kesari, Santosh ;

Borras, Ana M. ;

Bailey, Christopher ;

de Jong, Francisca ;

Jaenne, Pasi A. ;

Johnson, Bruce E. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) :4517-4520

[8] Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology [J].

Jänne, PA ;

Engelman, JA ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3227-3234

[9] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[10] Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer [J].

Miller, VA ;

Kris, WG ;

Shah, N ;

Patel, J ;

Azzoli, C ;

Gomez, J ;

Krug, LM ;

Pao, W ;

Rizvi, N ;

Pizzo, B ;

Tyson, L ;

Venkatraman, E ;

Ben-Porar, L ;

Memoli, N ;

Zakowski, M ;

Rusch, V ;

Heelan, RT .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1103-1109